ABL1 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

AFF1 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains AFF1 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

BCR is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains BCR status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

DEK is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains DEK status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains ELL status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

EWSR1 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 1 is open and 0 are closed. Of the trial that contains EWSR1 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains KMT2A status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

MECOM is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains MLLT1 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains MLLT10 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains MLLT3 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains MLLT4 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

MYCN is an inclusion eligibility criterion in 3 clinical trials for desmoplastic small round cell tumor, of which 3 are open and 0 are closed. Of the trials that contain MYCN status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains NRIP3 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NUP214 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains NUP214 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains RPN1 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

TP53 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [3].

WT1 is an inclusion eligibility criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].